Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Amgen Looks to Debut 3 Oncology Drugs in Next 3 Years: Global Commercial Chief
April 12, 2019
- Sanofi, Yakult Close Down Zaltrap Copromotion
April 12, 2019
- Sumitomo Dainippon to Soon Decide What to Do with ADHD Med Dasotraline after Setback
April 12, 2019
- Sumitomo Dainippon Shoots for Sales of 600 Billion Yen in FY2022, Revving Up “Post-Latuda” Pipeline Acquisition
April 12, 2019
- Mitsubishi Tanabe Joins Shonan iPark; 1st Pharma Company without Financial Ties to Takeda
April 12, 2019
- Shionogi Licenses Constipation Med to BioDelivery Sciences for Commercialization in US
April 12, 2019
- Teva Takeda Plans to Roll Out One AG Annually: CEO
April 11, 2019
- Kyowa to Skip May Listing for Enbrel Biosimilar, Codeveloper YL Biologics to Move Ahead
April 11, 2019
- Nearly 300 Kyowa Kirin Staffers Offer to Leave under Redundancy Program
April 11, 2019
- Hisamitsu Sales Down 3.4% on Price Cuts, Generic Erosion
April 11, 2019
- Diabetes Drug Imeglimin Hits Primary Goal in Japan PIII: Sumitomo, Poxel
April 10, 2019
- Xofluza Most Promoted Drug in January: Anterio
April 10, 2019
- Drug Makers Scratching Heads to Meet Daily Rep Report Requirements for New Detailing Guidelines
April 10, 2019
- Medipal’s Subsidiary to Distribute Stemirac in Japan
April 9, 2019
- Oncolys, Chugai Ink 50 Billion Yen Licensing Pact for Telomelysin
April 9, 2019
- Lixiana Waging Hand-to-Hand Combat with Xarelto in DOAC Market: Encise FY2018 Snapshot
April 8, 2019
- Novartis’ Eylea Challenger Could Reach Filing This Year for 2020 Launch
April 8, 2019
- 5 Industry-Academia Partners Tie Up for Research to Commercialize Renal Regenerative Medicine
April 8, 2019
- Japan Ethical Drug Sales Up 0.2% in February: Crecon
April 8, 2019
- FDA Accepts NDA Resubmission for Parkinson’s Drug Istradefylline: Kyowa Kirin
April 8, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…